Rigontec GmbH

Rigontec is a privately held biopharmaceutical company that develops RNA-based immunotherapeutics for the treatment of cancer and viral diseases. Its approach is based on a proprietary mechanism that engages the body’s anti-viral immune program, leading to the destruction of diseased cells and the induction of a lasting immune memory.

Details


Adresse:
Rigontec GmbH

Sigmund-Freud-Str. 25
53127 Bonn
Deutschland
Arbeitsgebiet:
Forschung & Entwicklung
Expansion:
national
Webseite:
Mitarbeiteranzahl:
1-10
Gründungsjahr:
2014